Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Prager, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Prager, R.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 46, Issue 4 607-614, Copyright © 1997 by American Diabetes Association


ARTICLES

Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes

A Kautzky-Willer, K Thomaseth, B Ludvik, P Nowotny, D Rabensteiner, W Waldhausl, G Pacini and R Prager
Department of Medicine III, University of Vienna, Austria.

Recent research indicates that islet amyloid pancreatic polypeptide (IAPP) might have a regulatory effect on beta-cell insulin processing and secretion. To study such interaction in more detail, IAPP secretion and kinetics and the serum concentrations of proinsulin were assessed both before and after delivery in lean pregnant women with gestational diabetes mellitus (GDM patients) in comparison to those with normal glucose tolerance (NGT) and to nonpregnant healthy lean (control) and obese insulin-resistant women during oral glucose tolerance tests. Kinetic analysis of IAPP was performed with mathematical modeling, providing indirect estimates of its secretion and fractional clearance. Total insulin secretion per 180 min was elevated by 30% in GDM patients (35 +/- 3 pmol/l) versus control subjects (27 +/- 1 pmol/l) (P < 0.05), but increased even more (190-250%) in obese insulin-resistant women, compared with all other groups (68 +/- 7 pmol/l, P < 0.0005). Pregnancy induced a more marked fourfold increase in apparent total IAPP secretion rate (TIR) (GDM patients, 172 +/- 31 pmol x 1(-1) x 3 h(-1); NGT subjects, 166 +/- 31 pmol x 1(-1) x 3 h(-1); control subjects, 40 +/- 1 pmol 1(-1) x 3 h(-1)) and a twofold rise in its fractional clearance versus control subjects (P < 0.01), whereas in GDM patients a 30% increase of IAPP secretion and a decreased clearance was found, compared with obese insulin-resistant women (TIR, 112 +/- 14 pmol x 1(-1) x 3 h(-1)). The increase in IAPP secretion in both pregnant groups was much higher than that of the insulin groups, resulting in a marked change of the IAPP-insulin cosecretion factor when compared with lean or obese nonpregnant women (P < 0.0005). Associated serum proinsulin and the postprandial (total divided by 180 min) proinsulin-to-insulin ratio were greater in GDM patients versus NGT and control subjects (0.11 +/- 0.01 vs. 0.07 +/- 0.01 and 0.08 +/- 0.01 pmol/l, P < 0.05), while the fasting proinsulin-to-insulin ratio was only increased in GDM patients versus control subjects (0.22 +/- 0.03 vs. 0.13 +/- 0.01 pmol/l, P < 0.05). After delivery, total IAPP secretion (52.4 +/- 1.5 pmol/l) was completely normalized in the GDM group, as were the clearance rate and the IAPP-insulin cosecretion factor. Similarly, serum proinsulin concentrations returned to normal, whereas proinsulin-to-insulin ratios remained elevated. In conclusion, IAPP hypersecretion is characteristic for pregnancy and might partially decrease hyperinsulinemia in pregnancy by inhibiting insulin secretion. Increased proinsulin concentrations and a raised proinsulin-to-insulin ratio, which did not abate following delivery, are specific to GDM and might thus serve as its marker and potentially even identify subjects at high risk for the development of NIDDM.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. Novials, L. Rodriguez-Manas, A. Chico, M. El Assar, S. Casas, and R. Gomis
Amylin and Hypertension: Association of an Amylin -G132A Gene Mutation and Hypertension in Humans and Amylin-Induced Endothelium Dysfunction in Rats
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1446 - 1450.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Stadler, C. Anderwald, T. Karer, A. Tura, T. Kastenbauer, M. Auinger, C. Bieglmayer, O. Wagner, F. Kronenberg, P. Nowotny, et al.
Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation: A sign of impaired {beta}-cell function?
Diabetes Care, May 1, 2006; 29(5): 1031 - 1038.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. Retnakaran, A. J.G. Hanley, M. Sermer, and B. Zinman
The Impact of Insulin Resistance on Proinsulin Secretion in Pregnancy: Hyperproinsulinemia is not a feature of gestational diabetes
Diabetes Care, November 1, 2005; 28(11): 2710 - 2715.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Tura, G. Pacini, A. Kautzky-Willer, B. Ludvik, R. Prager, and K. Thomaseth
Basal and dynamic proinsulin-insulin relationship to assess {beta}-cell function during OGTT in metabolic disorders
Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E155 - E162.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
N. G. Knowles, M. A. Landchild, W. Y. Fujimoto, and S. E. Kahn
Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes
Diabetes Care, February 1, 2002; 25(2): 292 - 297.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. N.M. Weijers, D. J. Bekedam, and Y. M. Smulders
Determinants of Mild Gestational Hyperglycemia and Gestational Diabetes Mellitus in a Large Dutch Multiethnic Cohort
Diabetes Care, January 1, 2002; 25(1): 72 - 77.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Tura, B. Ludvik, J. J. Nolan, G. Pacini, and K. Thomaseth
Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT
Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E966 - E974.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Homko, E. Sivan, X. Chen, E. A. Reece, and G. Boden
Insulin Secretion during and after Pregnancy in Patients with Gestational Diabetes Mellitus
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 568 - 573.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. L. Leahy and M. S. Fineman
Impaired phasic insulin and amylin secretion in diabetic rats
Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E457 - E462.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Kautzky-Willer, P. Fasching, B. Jilma, W. Waldhausl, and O. F. Wagner
Persistent Elevation and Metabolic Dependence of Circulating E-Selectin after Delivery in Women with Gestational Diabetes Mellitus
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4117 - 4121.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.